Raymond James Maintains Outperform on AbbVie, Raises Price Target to $181
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Gary Nachman has maintained an Outperform rating on AbbVie (NYSE:ABBV) and increased the price target from $177 to $181.
December 01, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James analyst Gary Nachman has reaffirmed AbbVie's Outperform rating and raised the price target to $181.
The increase in price target by Raymond James reflects a positive outlook on AbbVie's performance, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100